{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:57:59Z","timestamp":1792508279277,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":637,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1136\/esmoopen-2019-000610","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T04:34:18Z","timestamp":1578890058000},"page":"e000610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"S2","title":["How I treat cancer-associated thrombosis"],"prefix":"10.1016","volume":"4","author":[{"given":"Florian","family":"Moik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Pabinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-9717","authenticated-orcid":false,"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2019-000610_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001275","article-title":"Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Horsted","year":"2012","journal-title":"PLoS Med"},{"key":"10.1136\/esmoopen-2019-000610_bb0015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1136\/esmoopen-2019-000610_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2016.02.030","article-title":"Direct medical costs attributable to cancer-associated venous thromboembolism: a population-based longitudinal study","volume":"129","author":"Cohoon","year":"2016","journal-title":"Am J Med"},{"key":"10.1136\/esmoopen-2019-000610_bb0025","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/SLA.0000000000000378","article-title":"Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer","volume":"260","author":"Merkow","year":"2014","journal-title":"Ann Surg"},{"key":"10.1136\/esmoopen-2019-000610_bb0030","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/archinte.164.15.1653","article-title":"Outcomes and cost of deep venous thrombosis among patients with cancer","volume":"164","author":"Elting","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1136\/esmoopen-2019-000610_bb0035","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1136\/esmoopen-2019-000610_bb0040","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1136\/esmoopen-2019-000610_bb0045","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"S\u00f8rensen","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000610_bb0050","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","article-title":"Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis","volume":"18","author":"Hutten","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000610_bb0055","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000610_bb0060","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-Molecular-Weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000610_bb0065","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1160\/TH14-11-0977","article-title":"Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer","volume":"114","author":"Schulman","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1136\/esmoopen-2019-000610_bb0070","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","article-title":"Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials","volume":"1","author":"Prins","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1136\/esmoopen-2019-000610_bb0075","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/jth.13153","article-title":"Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the amplify trial","volume":"13","author":"Agnelli","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1136\/esmoopen-2019-000610_bb0080","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S2352-3026(16)30057-6","article-title":"Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial","volume":"3","author":"Raskob","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1136\/esmoopen-2019-000610_bb0085","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000610_bb0090","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000610_bb0095","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000610_bb0100","article-title":"Apixaban and dalteparin in active malignancy associated venous thromboembolism: the ADAM VTe trial","author":"McBane","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1136\/esmoopen-2019-000610_bb0105","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1055\/s-0038-1668523","article-title":"Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study","volume":"118","author":"Agnelli","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1136\/esmoopen-2019-000610_bb0110","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1136\/esmoopen-2019-000610_bb0115","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000610_bb0120","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","author":"Key","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000610_bb0125","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/rth2.12111","article-title":"Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review","volume":"2","author":"Samuelson Bannow","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1136\/esmoopen-2019-000610_bb0130","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1136\/esmoopen-2019-000610_bb0135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.phrs.2018.07.016","article-title":"Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)","volume":"135","author":"Gelosa","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1136\/esmoopen-2019-000610_bb0140","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1634\/theoncologist.2013-0239","article-title":"New oral anticoagulants and the cancer patient","volume":"19","author":"Short","year":"2014","journal-title":"Oncologist"},{"key":"10.1136\/esmoopen-2019-000610_bb0145","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1634\/theoncologist.2017-0473","article-title":"Use of direct oral anticoagulants in patients with cancer: practical considerations for the management of patients with nausea or vomiting","volume":"23","author":"Riess","year":"2018","journal-title":"Oncologist"},{"key":"10.1136\/esmoopen-2019-000610_bb0150","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11239-016-1465-x","article-title":"Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs)","volume":"43","author":"Hakeam","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1136\/esmoopen-2019-000610_bb0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11239-013-0907-y","article-title":"Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations","volume":"36","author":"Mani","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"10.1136\/esmoopen-2019-000610_bb0160","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/jcph.1097","article-title":"Regional gastrointestinal absorption of apixaban in healthy subjects","volume":"58","author":"Byon","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1136\/esmoopen-2019-000610_bb0165","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/jcph.540","article-title":"Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule","volume":"55","author":"Parasrampuria","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1136\/esmoopen-2019-000610_bb0170","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.amjmed.2016.12.033","article-title":"Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance","volume":"130","author":"Martin","year":"2017","journal-title":"Am J Med"},{"key":"10.1136\/esmoopen-2019-000610_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2019.07.003","article-title":"Extended treatment of cancer-associated thrombosis","volume":"181","author":"Marin-Romero","year":"2019","journal-title":"Thromb Res"},{"key":"10.1136\/esmoopen-2019-000610_bb0180","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-112206","article-title":"Wide variation in duration of anticoagulation after catheter-related thrombosis: a venous thromboembolism network US multicenter retrospective cohort study","volume":"132","author":"Baumann Kreuziger","year":"2018","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000610_bb0185","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/jth.12527","article-title":"Catheter-associated deep vein thrombosis of the upper extremity in cancer patients: guidance from the SSC of the ISTH","volume":"12","author":"Zwicker","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1136\/esmoopen-2019-000610_bb0190","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00277-014-2198-6","article-title":"Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study","volume":"94","author":"Kopolovic","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1136\/esmoopen-2019-000610_bb0195","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/jth.12883","article-title":"Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH","volume":"13","author":"Di Nisio","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1136\/esmoopen-2019-000610_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14218\/JCTH.2019.00008","article-title":"Update on management of portal vein thrombosis and the role of novel anticoagulants","volume":"7","author":"Wu","year":"2019","journal-title":"J Clin Transl Hepatol"},{"key":"10.1136\/esmoopen-2019-000610_bb0205","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.21037\/cdt.2017.09.16","article-title":"Tumor thrombus: incidence, imaging, prognosis and treatment","volume":"7","author":"Quencer","year":"2017","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1136\/esmoopen-2019-000610_bb0210","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTe disease: chest guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1136\/esmoopen-2019-000610_bb0215","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11239-015-1308-1","article-title":"Guidance for the management of venous thrombosis in unusual sites","volume":"41","author":"Ageno","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1136\/esmoopen-2019-000610_bb0220","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1136\/esmoopen-2019-000610_bb0225","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period","volume":"12","author":"Deitcher","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1136\/esmoopen-2019-000610_bb0230","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920300144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920300144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2019-000610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:23:54Z","timestamp":1761855834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920300144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":45,"alternative-id":["S2059702920300144"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000610","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How I treat cancer-associated thrombosis","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000610","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000610"}}